The European Medicines Agency (EMA) has published the agenda for the Committee for Medicinal Products for Veterinary Use (CVMP) meeting scheduled for 19-21 May 2026. The meeting will review applications for new veterinary medicines, discuss post-authorisation safety updates, and address ongoing scientific and regulatory issues affecting the veterinary sector.
The CVMP is EMA's scientific committee responsible for evaluating and supervising veterinary medicines in the EU. Its meetings typically cover marketing authorisation applications, variations to existing authorisations, and safety monitoring. The 19-21 May agenda includes discussions on maximum residue limits for pharmacologically active substances in food-producing animals, as well as updates on antimicrobial resistance.
Stakeholder impact
Veterinary pharmaceutical companies will be directly affected by the committee's decisions on new product approvals and label changes. Livestock farmers and veterinarians rely on CVMP recommendations for access to safe and effective treatments. Consumer and animal welfare groups monitor the committee's work on residue limits and antibiotic stewardship. National competent authorities in EU member states use CVMP opinions to inform their own regulatory actions.
Expected follow-up
Following the meeting, EMA will publish the CVMP meeting highlights and any adopted opinions. These opinions will inform the European Commission's final decisions on marketing authorisations and regulatory measures. The next CVMP meeting is scheduled for July 2026.